The EPA Takes Steps to Reduce PFAS Exposures in Drinking Water
These steps are in line with Endocrine Society recommendations. On April 10, the Biden-Harris Administration issued the first-ever national, legally enforceable drinking water standard to protect communities from exposure to harmful per-and polyfluoroalkyl substances (PFAS), also known as ‘forever chemicals.’ As part of the administration’s commitment to combatting PFAS, the Environmental Protection Agency (EPA) announced...
A Relentless Pursuit: JES Invites Collaborative Obesity Research
Endocrine Society Formalizes Partnership with the Korean Endocrine Society
On April 13, the Endocrine Society and the Korean Endocrine Society (KES) officially entered into a memorandum of Understanding (MOU) during the 12th Seoul International Congress of Endocrinology and Metabolism (SICEM) in conjunction with the 43rd Annual Scientific Meeting of the KES, which took place in Seoul, South Korea, April 11 – 13, 2024. This...
TIME Magazine recently recognized three Endocrine Society members in its 100 Most Influential People of 2024: Daniel J. Drucker, MD, professor of medicine, University of Toronto, Toronto, Canada, editor-in-chief, Endocrine Reviews; Joel F. Habener, MA, MD, chief of Laboratory of Molecular Endocrinology, Massachusetts General Hospital; and Svetlana Mojsov, PhD, research associate professor at Rockefeller University in...
Pandora’s Box? How Artificial Intelligence Could Impact Endocrinology
Like it or not, artificial intelligence (AI) is here to stay, and its impact on both the science and practice of endocrinology will soon be quite evident. The ENDO 2024 Plenary session, “Artificial Intelligence in Health and Biomedical Research: The Future Is Now,” will no doubt answer many questions on the minds of endocrinologists in...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Clinical Trial Interim Data Show Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome On April 11, Amylyx Pharmaceuticals announced interim data from the ongoing Phase 2 HELIOS clinical trial of AMX0035 (sodium phenylbutyrate [PB] and...